CA
PCRX icon

Continuum Advisory’s Pacira BioSciences PCRX Stock Holding History

Continuum Advisory’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-27
Closed -$509 – 1862
2024
Q4 		$509 Hold
27
– – ﹤0.01% 1731
2024
Q3 		$442 Buy
+27
New +$462 ﹤0.01% 1814

Other funds holding PCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DPCM
Doma Perpetual Capital Management Miami, Florida $372M AUM 14.96% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Continuum Advisory's PCRX Position: Q1 2025 in Review

Continuum Advisory sold out of Pacira BioSciences (PCRX) in Q1 2025, closing a stake of 27 shares — an estimated $509 sold.

Continuum Advisory first reported a position in PCRX in Q3 2024 and held it in 2 quarters. The position peaked at $509 in Q4 2024. 235 funds tracked by Wall St. Rank hold PCRX as of Q1 2025.

  • Continuum Advisory reported no remaining Pacira BioSciences position as of Q1 2025 after selling out during the quarter.
  • Continuum Advisory sold 27 Pacira BioSciences shares in Q1 2025, an estimated $509.
  • Continuum Advisory first reported a position in Pacira BioSciences in Q3 2024 and held it in 2 quarters.
  • Continuum Advisory's Pacira BioSciences position peaked at $509 in Q4 2024.
  • 235 funds tracked by Wall St. Rank held Pacira BioSciences as of Q1 2025.

Based on Continuum Advisory's 13F filing for Q1 2025, filed 23 Apr 2025.